These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 33768656)

  • 21. Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients.
    Winston DJ; Limaye AP; Pelletier S; Safdar N; Morris MI; Meneses K; Busuttil RW; Singh N
    Am J Transplant; 2014 Dec; 14(12):2758-64. PubMed ID: 25376267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Invasive Fungal Breakthrough Infections under Targeted Echinocandin Prophylaxis in High-Risk Liver Transplant Recipients.
    Breitkopf R; Treml B; Senoner T; Bukumirić Z; Rajsic S
    J Fungi (Basel); 2023 Feb; 9(2):. PubMed ID: 36836384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Impact of Antifungal Prophylaxis in Lung Transplant Recipients.
    Pennington KM; Dykhoff HJ; Yao X; Sangaralingham LR; Shah ND; Peters SG; Barreto JN; Razonable RR; Kennedy CC
    Ann Am Thorac Soc; 2021 Mar; 18(3):468-476. PubMed ID: 32962402
    [No Abstract]   [Full Text] [Related]  

  • 24. Hematopoietic SCT in patients with a history of invasive fungal infection.
    Zhang P; Song A; Wang Z; Feng S; Qiu L; Han M
    Bone Marrow Transplant; 2009 Apr; 43(7):533-7. PubMed ID: 19104496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of Invasive Fungal Infections in Liver Transplant Recipients under Targeted Echinocandin Prophylaxis.
    Breitkopf R; Treml B; Simmet K; Bukumirić Z; Fodor M; Senoner T; Rajsic S
    J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36836055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted versus universal antifungal prophylaxis among liver transplant recipients.
    Eschenauer GA; Kwak EJ; Humar A; Potoski BA; Clarke LG; Shields RK; Abdel-Massih R; Silveira FP; Vergidis P; Clancy CJ; Nguyen MH
    Am J Transplant; 2015 Jan; 15(1):180-9. PubMed ID: 25359455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.
    Chou LS; Lewis RE; Ippoliti C; Champlin RE; Kontoyiannis DP
    Pharmacotherapy; 2007 Dec; 27(12):1644-50. PubMed ID: 18041885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Universal prophylaxis with fluconazole for the prevention of early invasive fungal infection in low-risk liver transplant recipients.
    San-Juan R; Aguado JM; Lumbreras C; Fortun J; Len O; Muñoz P; Montejo M; Moreno A; Cordero E; Blanes M; Ramos A; de la Torre-Cisneros J; Lopez-Medrano F; Carratala J; Moreno E;
    Transplantation; 2011 Aug; 92(3):346-50. PubMed ID: 21709604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
    Busca A; Candoni A; Audisio E; Passera R; Bruno B; Monaco F; Mordini N; Vacca A; Delia M; Aversa F; Pagano L
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2214-2219. PubMed ID: 27667012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High incidence of invasive fungal infection during acute myeloid leukemia treatment in a resource-limited country: clinical risk factors and treatment outcomes.
    Nganthavee V; Phutthasakda W; Atipas K; Tanpong S; Pungprasert T; Dhirachaikulpanich D; Krithin S; Tanglitanon S; Jutidamronphang W; Owattanapanich W; Chayakulkeeree M; Phikulsod P
    Support Care Cancer; 2019 Sep; 27(9):3613-3622. PubMed ID: 31165931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients.
    Saliba F; Pascher A; Cointault O; Laterre PF; Cervera C; De Waele JJ; Cillo U; Langer RM; Lugano M; Göran-Ericzon B; Phillips S; Tweddle L; Karas A; Brown M; Fischer L; ;
    Clin Infect Dis; 2015 Apr; 60(7):997-1006. PubMed ID: 25520332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of antifungal prophylaxis in high-risk liver transplant recipients.
    Hadley S; Huckabee C; Pappas PG; Daly J; Rabkin J; Kauffman CA; Merion RM; Karchmer AW
    Transpl Infect Dis; 2009 Feb; 11(1):40-8. PubMed ID: 19144094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients.
    Castroagudín JF; Pontón C; Bustamante M; Otero E; Martínez J; Tomé S; Conde R; Segade FR; Delgado M; Brage A; Galbán C; Varo E
    Transplant Proc; 2005 Nov; 37(9):3965-7. PubMed ID: 16386598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.
    Stern A; Su Y; Lee YJ; Seo S; Shaffer B; Tamari R; Gyurkocza B; Barker J; Bogler Y; Giralt S; Perales MA; Papanicolaou GA
    Biol Blood Marrow Transplant; 2020 Jun; 26(6):1195-1202. PubMed ID: 32088367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Micafungin prophylaxis in routine medical practice in adult and pediatric patients with hematological malignancy: a prospective, observational study in France.
    El Cheikh J; Ceballos P; Dalle JH; Ducastelle-Leprêtre S; Dulon E; Herbrecht R
    Diagn Microbiol Infect Dis; 2019 Jul; 94(3):268-273. PubMed ID: 30842034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: A propensity score analysis.
    Fortún J; Muriel A; Martín-Dávila P; Montejo M; Len O; Torre-Cisneros J; Carratalá J; Muñoz P; Fariñas C; Moreno A; Fresco G; Goikoetxea J; Gavaldá J; Pozo JC; Bodro M; Vena A; Casafont F; Cervera C; Silva JT; Aguado JM;
    Liver Transpl; 2016 Apr; 22(4):427-35. PubMed ID: 26709146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients.
    Fortún J; Martín-Dávila P; Montejo M; Muñoz P; Cisneros JM; Ramos A; Aragón C; Blanes M; San Juan R; Gavaldá J; Llinares P;
    Transplantation; 2009 Feb; 87(3):424-35. PubMed ID: 19202450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liposomal amphotericin B for prophylaxis of invasive fungal infections in high-risk paediatric patients with chemotherapy-related neutropenia: interim analysis of a prospective study.
    Uhlenbrock S; Zimmermann M; Fegeler W; Jürgens H; Ritter J
    Mycoses; 2001 Dec; 44(11-12):455-63. PubMed ID: 11820258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Invasive fungal infections associated with prior respiratory viral infections in immunocompromised hosts.
    Ajmal S; Mahmood M; Abu Saleh O; Larson J; Sohail MR
    Infection; 2018 Aug; 46(4):555-558. PubMed ID: 29627936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: a systematic review.
    Pechlivanoglou P; Le HH; Daenen S; Snowden JA; Postma MJ
    J Antimicrob Chemother; 2014 Jan; 69(1):1-11. PubMed ID: 23975736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.